Showing 41-50 of 7739 results for "".
Physician Spotlight: Robert S. Kirsner, MD, PhD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-robert-s-kirsner-md-phd-faad/20319/It's time to get wound up about wound care.Cutaneous T-Cell Lymphoma: Mogamulizumab as a Novel Treatment for Refractory Mycosis Fungoides and Sezary Syndrome
https://practicaldermatology.com/youngmd-connect/resident-resource-center/Cutaneous-T-Cell-Lymphoma-Mogamulizumab-as-a-Novel-Treatment-for-Refractory-Mycosis-Fungoides-and-Sezary-Syndrome/23409/An overview of the diagnosis and prognosis of CTCL.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.DermWireTV: Skyrizi for PsA; Toxins and Wound Healing at Maui Derm; SDDS Registration
https://practicaldermatology.com/topics/psoriasis/skyrizi-for-psa-toxins-and-wound-healing-at-maui-derm-sdds-registration-dermwiretv/20057/Skyrizi (AbbVie) is now approved for the treatment of adults with active psoriatic arthritis. Michael Gold, MD was among the speakers who offered updates on cosmetic trends as well as medical care at Maui Dermatology for Dermatologists last week. He spoke about high-dose neurotoxins. Robert KirsnerFDA Approval for Delgocitinib
https://practicaldermatology.com/series/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.Seborrheic Dermatitis Approaches and Stopping Biologic Treatment for Atopic Dermatitis
https://practicaldermatology.com/conferences/scale-2025/seborrheic-dermatitis-approaches-and-stopping-biologic-treatment-for-atopic-dermatitis/35896/Naiem T. Issa, MD, PhD, talks at Music City SCALE 2025 about how to approach seborrheic dermatitis, as well as what happens to atopic dermatitis patients after ending biologic treatments.Driving Growth in the Dermatology Practice
https://practicaldermatology.com/topics/practice-management/driving-growth-in-the-dermatology-practice/18630/Robert Rullo reminds dermatologists to think beyond being just a clinician and to remember they are also running a business. He discusses key business philosophies clinicians need to be aware of and common obstacles that inhibit geometric practice growth. GenerationsDermaBlade®
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermablade/19851/DermaBlade, the easier to grip and use sterile biopsy blade. Watch this video to learn more about DermaBlade from the inventor, Robert Segal, MD.The Business of Dermatology
https://practicaldermatology.com/topics/practice-management/the-business-of-dermatology/19725/Are you a dermatologist who runs a practice, or a business owner who happens to be a dermatologist? Robert Rullo challenges clinicians to rethink how they approach running their practice.Journal Club: Comparing Recommendations from Different AD Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-comparing-recommendations-from-different-ad-guidelines/24466/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a pediatric dermatologist at Seattle Children's Hospital, about some of the differences in recommendations from the Annals of Allergy, Asthma, and Immunology Joint Task Force AD guidelines, and the Journal of the American Academy of Dermatology (JAA